Syn-tech Chemical & Pharmaceutical Co. Ltd. · TPEX:1777
Syn-tech Chemical & Pharmaceutical — Syn-Tech Chem. & Pharm. — Industry Forum 2026
24 slides from Syn-tech Chemical & Pharmaceutical's conference presentation, May 15, 2026
Slide 1: Syn-Tech Chem. & Pharm. Industry Forum
Add You Text Here Add You Text Here 此处添加标题 SYN-TECH CHEM.& PHARM.CO.,LTD 15 May, 2026 Industry Forum Chen-Ming, Hsiao Chairman Stock Code：1777
Slide 2: Disclaimer
DISCLAIM ER S Y N - T EC H C H EM . & P H A RM . In these presentations and discussions, there are certain forward- looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on cir
Slide 3: Contents
CON T EN T S S Y N - T EC H C H EM . & P H A RM . 01 Company Brief Introduction CONTENTS Company profile Main Products P.04 — P.09 202 6 INVESTOR CONFERENC E DMF/MF Registration Status Official and Customer Audit Records This presentation will begin with a company brief introduction, review 02 Perfo
Slide 4: Company Brief Introduction
S Y N - T E C H · 17 7 7 01 Company Brief Introduction Company profile Main products DMF/MF registration status Official and customer audit records COM PA N Y PROFI L E 04 / 24
Slide 5: Company Profile
0 1 · C O M PA N Y P R O F I L E S Y N - T EC H C H EM . & P H A RM . CORPORATE CORE VALUES C E R T I F I C AT I O N S ISO 9001 Quality management systems ISO 14001 Environmental management Sincerity Honesty Development Innovation systems ISO 45001 Occupational health and safety management systems P
Slide 6: Main Products
0 1 · PRODU C T PORT FOLI O Main products S Y N - T EC H C H EM . & P H A RM . Our ten major product lines cover key therapeutic areas including muscle relaxation, gastrointestinal, neurological, respiratory, and cardiovascular treatments, while also extending into veterinary pharmaceuticals and exc
Slide 7: Global DMF/MF Footprint
0 1 · D M F / M F R E G I S T R AT I O N S Y N - T EC H C H EM . & P H A RM . G LO BA L D M F / M F F O O T P RI N T C OU NT RY D MF /MF R E G I S T R A T I O N US JP U.S.A JAPAN 20 21 69 items global registrations, covering7 major regional markets CA CANADA 3 KR KOREA 6 JP 21 US 20 others 9 EU 6 KR
Slide 8: Official Audits
0 1 · OFFICIAL AUDITS S Y N - T EC H C H EM . & P H A RM . Successfully passed official inspections by eight major global regulatory authorities, with a cumulative total of 43 audit records, establishing a solid foundation for international regulatory compliance. 1995 2002 2007 2008 U.S.A FDA Taiwan
Slide 9: Customer Audits
0 1 · C UST OM ER AUDI T S S Y N - T EC H C H EM . & P H A RM . C U S T O M ER A U D I T S 5 122 2020 2021 7 2022 11 Cumulative Inspections Completed 2023 35 (2020–2025) 2024 38 Since 2023, the number of customer 2025 26 audits has increased significantly, reflecting international customers’ strong
Slide 10: Performance for Operation
S Y N - T E C H · 17 7 7 02 Performance for Operation Revenue of Product / Y ear-over-Year EPS and Dividend Recent 5 Years Regional Structure Operating Comparison OPERAT I N G RESU LT S 10 / 2 4
Slide 11: 5-Year Revenue
0 2 · 5 - Y EAR REV EN UE S Y N - T EC H C H EM . & P H A RM . Unit : NT in million 1,400 1,300 1,300 1,258 1,200 1,115 1,100 986 1,000 900 800 747 700 600 500 400 300 276 200 100 0 2021 2022 2023 2024 2025 Jan.-Mar., 2026 (retrospective adjustment) 2023 / 2022 2024 / 2023 2025 / 2024 +13.1% +12.8%
Slide 12: Product Mix 2025 vs 2024
0 2 · PRODU CT M I X 2025 vs 2024 S Y N - T EC H C H EM . & P H A RM . Unit : NT in ten thousand 50,000 36% 45,000 40,000 35,000 26% 30,000 19% 25,000 20,000 12% 11% 11% 12% 15,000 11% 9% 8% 7% 10,000 6% 7% 6% 5% 5% 4% 3% 5,000 1% 1% 0 Non- Steroidal Topical Anti- Central Nervous Respiratory Excipie
Slide 13: Product Mix 2026 Q1 vs 2025 Q1
0 2 · PRODU CT M I X 2026 Q1 vs 2025 Q1 S Y N - T EC H C H EM . & P H A RM . Unit : NT in ten thousand 12,000 10,000 34% 30% 8,000 6,000 21% 14% 14% 4,000 12% 11% 8% 8% 9% 7% 6% 6% 7% 2,000 4% 3% 2% 2% 1% 1% 0 Non- Steroidal Topical Anti- Muscle Central Nervous Respiratory Excipient and Cardiovascul
Slide 14: Regional Mix 2025
0 2 · REGI ON AL M I X · 2 0 2 5 S Y N - T EC H C H EM . & P H A RM . Data collected ：Year 2025 Japan 40% Asia (Except Taiwan and Japan) 20% 2 0 2 5 Full-Year Sales Europe 16% 100% Americas 13% 6 Major Regions Taiwan 9% Others 2% SY N - T ECH 17 7 7 14 / 2 4
Slide 15: Regional Mix Q1 2026
0 2 · REGI ON AL M I X · 2 0 2 6 Q1 S Y N - T EC H C H EM . & P H A RM . Data collected ：Jan.- Mar., 2026 Japan 43% Asia (Except Taiwan and Japan) 19% 2 0 2 6 Jan.-Mar. Sales Europe 20% 100% Americas 8% 6 Major Regions Taiwan 8% Others 2% SY N - T ECH 17 7 7 15 / 2 4
Slide 16: Revenue Compared Between 2025 and 2024
0 2 · Y OY C OM PA RI SON Revenue Compared Between 2025 and 2024 S Y N - T EC H C H EM . & P H A RM . Unit : NT in thousand Operating revenue Operating profit Profit after tax EPS (in dollar) 1,300,241 319,861 261,609 5.87 ▲+ 3% ▼ -9% ▼ -33% ▼ -33% ITEM 2025 2024 Differences (%) Operating revenue 1,
Slide 17: YoY Analysis 2025 vs 2024
0 2 · Y OY A N A LY SI S The Differences Between 2025 and 2024 S Y N - T EC H C H EM . & P H A RM . SALES GROWTH DRIVERS OPERATING SUMMARY The increase in revenue was mainly driven by sales This was mainly due to price competition in growth from exports to the Japanese market. export markets, exchan
Slide 18: Revenue Compared Between 2026 Q1 and 2025 Q1
0 2 · Y OY C OM PA RI SON · Q1 Revenue Compared Between 2026 Q1 and 2025 Q1 S Y N - T EC H C H EM . & P H A RM . Unit : NT in thousand Operating revenue Operating profit Profit after tax EPS (in dollar) 275,573 77,735 71,651 1.61 ▼-13% ▼-7% ▼-5% ▼-5% ITEM Jan.- Mar., 2026 Jan.- Mar., 2025 Difference
Slide 19: YoY Analysis Q1 2026 vs Q1 2025
0 2 · Y OY A N A LY SI S · Q1 The Differences Between 2026 Q1 and 2025 Q1 S Y N - T EC H C H EM . & P H A RM . SALES GROWTH DRIVERS OPERATING SUMMARY ·Due to climate changes, customers adjusted ·Although revenue declined, changes in the their procurement schedules, resulting in product sales mix led
Slide 20: EPS and Dividend in Recent Years
0 2 · EPS & D I V I D EN D EPS and Dividend in Recent 5 Years S Y N - T EC H C H EM . & P H A RM . Unit : NT in dollar 10.00 9.00 8.82 8.00 7.00 6.62 5.3 5.87 6.00 5.63 5.00 3.5 4.0 4.00 3.38 3.0 3.00 1.93 2.00 1.61 1.00 0.00 2021 2022 2023 2024 2025 Jan.-Mar., 2026 (retrospective adjustment) EPS Ca
Slide 21: Future Strategies and Forward-looking
S Y N - T E C H · 17 7 7 03 Future Strategies and Forward -looking Strategy in the Future Development & forward - looking FU T U RE ST RAT EGY 21 / 2 4
Slide 22: Strategy: Steady Growth in Product Sales Volume
0 3 · ST RAT EGY · PA RT I Strategy in the Future Development & forward-looking Ⅰ S Y N - T EC H C H EM . & P H A RM . P RO D U C T M O M E N T U M Steady growth in product sales volume Annual sales of AMH reached 3.8 metric tons; DFP exceeded1.9 metric tons in sales; and NTP, actively expanding int
Slide 23: Strategy: Niche Products and New Business Areas
0 3 · ST RAT EGY · PA RT I I Strategy in the Future Development & forward-looking Ⅱ S Y N - T EC H C H EM . & P H A RM . Prudently evaluate future niche products Expand into new business areas In alignment with national policy needs, strategically selected 01 Evaluate key intermediates of APIs and s
Slide 24: Thanks for your attention
SYN-TECH CHEM.& PHARM.CO.,LTD Thanks for your attention Stock Code：1777